ITGR:NYE-Integer Holdings Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 123.27

Change

+5.36 (+4.55)%

Market Cap

USD 0.84B

Volume

1.11M

Analyst Target

USD 100.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Integer Holdings Corp is the medical device outsource manufacturer serving the energy, military, and environmental markets. The Company's brands include Greatbatch Medical, Lake Region Medical and Electrochem.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.02 (-0.02%)

USD 183.79B
SYK Stryker Corporation

+1.82 (+0.56%)

USD 133.55B
MDT Medtronic PLC

+0.77 (+0.95%)

USD 112.28B
BSX Boston Scientific Corp

+0.82 (+1.14%)

USD 105.90B
EW Edwards Lifesciences Corp

+0.19 (+0.22%)

USD 55.80B
ZBH Zimmer Biomet Holdings Inc

+3.20 (+2.70%)

USD 26.16B
STE STERIS plc

+1.58 (+0.77%)

USD 21.09B
PHG Koninklijke Philips NV ADR

+0.26 (+0.98%)

USD 18.20B
SNN Smith & Nephew SNATS Inc

+0.34 (+1.39%)

USD 10.70B
BIO Bio-Rad Laboratories Inc

+0.52 (+0.19%)

USD 7.97B

ETFs Containing ITGR

PSCH Invesco S&P SmallCap Heal.. 3.63 % 0.29 %

+0.38 (+1.06%)

USD 0.20B
ETHO Etho Climate Leadership U.. 0.00 % 0.45 %

+0.52 (+1.06%)

USD 0.18B
FNX First Trust Mid Cap Core .. 0.00 % 0.62 %

+1.05 (+1.06%)

USD 1.16B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+1.13 (+1.06%)

USD 0.25B
JELS:LSE 0.00 % 0.00 %

N/A

N/A
JLES:LSE 0.00 % 0.00 %

N/A

N/A
JLSP:LSE 0.00 % 0.00 %

N/A

N/A
JPQE:F 0.00 % 0.00 %

N/A

N/A
JPQE:XETRA 0.00 % 0.00 %

N/A

N/A
TPSC Timothy Plan US Small Cap.. 0.00 % 0.00 %

+0.37 (+1.06%)

USD 0.14B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.41% 82% B 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.41% 82% B 94% A
Trailing 12 Months  
Capital Gain 51.60% 87% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.60% 87% B+ 91% A-
Trailing 5 Years  
Capital Gain 77.60% 85% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.60% 85% B 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 7.44% 48% F 65% D
Dividend Return 7.44% 48% F 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.17% 67% D+ 43% F
Risk Adjusted Return 28.43% 61% D- 52% F
Market Capitalization 0.84B 56% F 73% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.04 52% 14%
Price/Book Ratio 2.55 56% 34%
Price / Cash Flow Ratio 21.59 41% 15%
Price/Free Cash Flow Ratio 18.82 30% 16%
Management Effectiveness  
Return on Equity 6.17% 66% 43%
Return on Invested Capital 6.25% 71% 50%
Return on Assets 3.99% 69% 64%
Debt to Equity Ratio 63.19% 18% 52%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector